Latest filing published 10 Jul 2026 for CG Oncology, Inc., €1.3M.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
James Mulay: trading record in brief
James Mulay discloses dealings in CG Oncology, Inc. to SEC (Form 4). We count 2 filings; the first trade dates from 1 July 2026 and the latest from 10 July 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The newest entry dates from 10 July 2026: a transaction of €1.3M, in CG Oncology, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to James Mulay
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 20,237 shares@ US$73.32CommonSEC144:0001950047-26-007021
- 3,928 shares@ US$71.05CommonSEC144:0001950047-26-006790
2 of 2 declarations
